Literature DB >> 36264330

[Renal manifestations in rheumatoid arthritis and spondylarthritis].

Elisabeth Märker-Hermann1.   

Abstract

As systemic diseases it is not uncommon for inflammatory rheumatic diseases to exhibit renal involvement. In contrast to connective tissue diseases and vasculitis, in rheumatoid arthritis and spondylarthritis direct inflammatory manifestations in the sense of glomerulonephritis (GN) and autoimmune interstitial nephritis are rare. In these groups of diseases renal biopsies usually show mesangial proliferative GN and IgA nephropathy or less commonly membranous GN. These and secondary amyloid A (AA) amyloidosis are regularly associated with longer lasting disease activity and a poor prognosis; however, clinically more frequent and more relevant are other sequelae of chronic systemic inflammation, namely endothelial function disorder and the premature development of atherosclerosis, resulting in progressive kidney failure. This is accompanied by the undesired effects of antirheumatic treatment and renal complications of comorbidities.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Comorbidity; Kidney failure; Psoriatic arthritis; Systemic inflammatory disease; Urinalysis

Year:  2022        PMID: 36264330     DOI: 10.1007/s00393-022-01279-1

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.530


  2 in total

1.  Psoriatic nephropathy--does an entity exist?

Authors:  N P Singh; Anupam Prakash; Samir Kubba; Anirban Ganguli; Anil K Singh; Sunandan Sikdar; Satish K Agarwal; Amit K Dinda; Chander Grover
Journal:  Ren Fail       Date:  2005       Impact factor: 2.606

2.  Increased cause-specific mortality in patients with mild and severe psoriasis: a population-based Swedish register study.

Authors:  Axel Svedbom; Johan Dalén; Carla Mamolo; Joseph C Cappelleri; Lotus Mallbris; Ingemar F Petersson; Mona Ståhle
Journal:  Acta Derm Venereol       Date:  2015-09       Impact factor: 4.437

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.